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A B S T R A C T
Physiological changes during embryonic development are associated with changes in the isoform expression of
both myocyte sarcomeric proteins and of erythrocyte haemoglobins. Cell type-speciﬁc isoform expression of
these genes also occurs. Although these changes appear to be coordinated, it is unclear how changes in these
disparate cell types may be linked. The transcription factor Hic2 is required for normal cardiac development and
the mutant is embryonic lethal. Hic2 embryos exhibit precocious expression of the deﬁnitive-lineage hae-
moglobin Hbb-bt in circulating primitive erythrocytes and of foetal isoforms of cardiomyocyte genes (creatine
kinase, Ckm, and eukaryotic elongation factor Eef1a2) as well as ectopic cardiac expression of fast-twitch skeletal
muscle troponin isoforms. We propose that HIC2 regulates a switching event within both the contractile ma-
chinery of cardiomyocytes and the oxygen carrying systems during the developmental period where demands on
cardiac loading change rapidly.
1. Introduction
The transition from embryonic to foetal development is associated
with major changes in physiology. Increased cardiac loading as a result
of the gain in size requires improved cardiomyocyte performance. The
heart rate increases from 125 bpm to 194 bpm between E10.5 and
E14.5 [1]. Cardiomyocytes, in common with other muscle cell types,
are highly plastic and are able to adapt to meet this demand by altering
the expression of sarcomeric proteins, metabolic enzymes and other
proteins [2,3]. This increased workload requires an increased supply of
oxygen and this is met by changes in haemoglobin expression within
circulating erythrocytes [4] and upregulation of myoglobin in cardio-
myocytes [5]. These changes are mediated by a coordinated transition
from an embryonic to a foetal gene expression programme in both
cardiomyocytes and in erythrocytes.
Sarcomeric proteins such as myosin, actin, myomesin and troponin
exist in multiple isoforms, each with distinct physiological properties,
and these may be exploited by the embryo to ﬁne tune performance
[6–8] . Multiple isoforms of these proteins appear to have evolved by
duplication of a common ancestral gene, followed by a process of di-
vergence and adaptation [9,10]. This has led to great diversity. For
example, there are 10 isoforms of myosin heavy chain [11] and three
isoforms of troponin T [12]. Cardiomyocytes, smooth muscle, fast
skeletal muscle and slow skeletal muscle exhibit muscle-speciﬁc
isoform expression; these isoforms are each adapted to a speciﬁc
function and are non-redundant [13,14]. In addition, each muscle type
exhibits maturational changes in isoform expression, an adaptation to
changing demands [7,15]. Similarly, a number of isoforms of both
alpha and beta haemoglobins have evolved by gene duplication, these
exhibit distinct aﬃnities for oxygen and are expressed within circu-
lating erythrocytes in a developmentally regulated sequence [4,16,17].
Expression of the cardiomyocyte globin, myoglobin, is initiated in the
foetal period [5]. Maturational isoform switching is also seen in me-
tabolic enzymes such as creatine kinase, which supplies energy to
muscle, and exists as two isoforms expressed in a developmentally
regulated sequence [18,19]. Pathological conditions leading to hypoxia
such as ischaemia, heart failure and atrial ﬁbrillation, can result in a
recapitulation of the cardiomyocyte foetal or embryonic gene expres-
sion programme [20–22].
HIC2 is a transcription factor related to the tumour suppressor HIC1
[23], required for normal cardiac development and lost in distal var-
iants of 22q11 Deletion Syndrome [24]. Mice heterozygous for Hic2
have a ventricular septal defect and exhibit peri-natal lethality [24].
Homozygous loss of function mutants, in contrast, exhibit early em-
bryonic lethality [24], occurring before septation of the heart begins. In
an eﬀort to understand the cause of this lethality, we uncovered evi-
dence to suggest that HIC2 may play a role in the regulation of isoform
expression in both cardiomyocytes and primitive erythrocytes. We
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show that HIC2 acts to suppress expression of foetal isoforms, which are
normally turned on at a time when Hic2 expression is decreasing. In the
absence of Hic2, foetal genes are precociously expressed in both cell
types and lineage speciﬁc troponin expression is disrupted.
2. Results
2.1. Hic2 loss results in developmental delay and early embryonic lethality
Examination of Hic2GT/GT loss of function mutants revealed that
embryonic developmental is slower in these embryos relative to litter-
mate controls. We found that mutant embryos harvested at day E9.5
appeared younger than littermates and exhibited a comparable
anatomy to wildtype embryos harvested at E8.5 (Fig. 1a). This delay
could not be explained by reduced proliferation or increased apoptosis
because no diﬀerences were observed in the number of cells positive for
either phosphorylated histone H3 and cleaved caspase 3 (data not
shown). Embryos also exhibited early embryonic lethality, with few
mutant embryos recovered after E9.5 (Fig. 1a).
2.2. Foetal genes are precociously expressed in the Hic2 mutant
Early lethality and reduced size made further analysis of loss-of-
function mutants impossible. We therefore turned to a milder, condi-
tional mutant. Mesp1Cre drives deletion in both cardiac and extra-car-
diac derivatives of the anterior mesoderm, the latter including a subset
of the haematopoietic system. Hic2FL/FL; Mesp1Cre/+ embryos exhibit
only a partially penetrant lethality (26% at E13.5), which occurs later
in gestation than in Hic2GT/GT embryos [24].
Gene expression analysis was performed in the Hic2FL/FL; Mesp1Cre/+
embryo at E9.5 on the isolated heart tube. The samples consisted of
cardiovascular tissue together with the blood contained within it.
Erythrocytes in circulation at E9.5 are largely nucleated, primitive-
lineage erythrocytes which carry mRNA. 62 genes showed> 1.5 fold
change (Fig. 1b). The largest changes were seen in upregulated genes
(max change 12.1) with only modest changes in downregulated genes
(> 0.51). The most changed genes were found to be the beta hae-
moglobin, Hbb-bt (+12.1) and the creatine kinase enzyme isoform Ckm
(+6.78). Strikingly, these are both genes whose expression is normally
initiated later in development during the foetal period. We hypothe-
sised that loss of Hic2 may result in precocious expression of a foetal
gene expression programme. To test this, we compared these data to a
dataset we have previously published derived from the wildtype E13.5
embryo [24] . We plotted the ratio of expression in the wildtype embryo
at E13.5 relative to E9.5, against the change in expression in the E9.5
mutant relative to E9.5 wildtype (Fig. 1c). Many genes which show an
increase in the Hic2 mutant at E9.5, suggesting Hic2 repression, were
seen to be more highly expressed later in development (Fig. 1c). Genes
showing a decrease in the mutant, which are activated downstream of
Hic2, did not show strong changes in the mutant, but broadly speaking
were more strongly expressed in the embryo than in the foetus.
This analysis raises the intriguing possibility that HIC2 may function
to repress expression of foetal genes in order to maintain the heart and
circulatory system in an embryonic state.
2.3. HIC2 regulates haemoglobin isoform switching
The most changed gene on the microarray was the beta hae-
moglobin, Hbb-bt. Haemoglobin is a tetramer consisting of two alpha
and two beta haemoglobin molecules, several isoforms of each exist in
Fig. 1. Hic2 regulates the timing of gene expression in the heart and blood.
a. Wholemount images of wildtype (left) and Hic2GT/GT embryos (right), E9.5 embryos are stained with X-Gal to show expression of the genetrap cassette from the Hic2 locus. Mutants are
delayed by approximately one day of development and are small in size. Embryos are recovered at the Mendelian ratio until day E9.5 but show lethality after this age (Table).
b. The graph shows genes changed in a microarray analysis of the Mesp1Cre Hic2 conditional mutant at E9.5. Fold change (log2 scale) is plotted against p-value (− log10 scale).
c. The change in expression over developmental time (change between E13.5 and E9.5 in the wildtype condition) is plotted against change in the Hic2 conditional mutant at E9.5 (E9.5
WT/KO). Genes that are expressed more strongly at E13.5 than at E9.5 may be considered foetal genes while those expressed more strongly at E9.5 may be considered as embryonic.
Yellow lines represent a 4 fold change. ρ indicates Pearson's Correlation coeﬃcient calculated from log-transformed values.
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the genome with distinct physiological properties and these are classi-
ﬁed as either embryonic or deﬁnitive, based on the timing of expression
[4]. Primitive lineage erythrocytes are derived from MESP1+ pre-
cursors in the yolk-sac [25], and express the embryonic haemoglobins,
Hbb-bh and Hbb-y. At day E11.5 the major site of erythropoiesis moves
from the yolk sac to the liver, and the resulting liver-derived deﬁnitive
lineage expresses only the deﬁnitive haemoglobins, Hbb-bt and Hbb-bs
[4]. These latter genes are derived from independent loci but have an
identical sequence and thus are indistinguishable in either microarray
or qPCR assays. Thus, we observe expression of deﬁnitive haemoglobins
(Hbb-bt and/or Hbb-bs) at a time when only primitive erythrocytes are
in circulation, indicating dysregulation of gene expression in these cells.
To begin to explore this phenomenon we ﬁrst asked whether Hic2 is
expressed in primitive erythrocytes or their precursors. X-gal staining of
Hic2GT/+ embryos revealed strong reporter gene expression in the yolk
sac at E9.5, in addition to the previously reported heart expression
(Fig. 2a). Thus, Hic2 is expressed at the site of primitive lineage ery-
thropoiesis. Mesp1 is known to be expressed in yolk sac blood islands
and primitive erythrocytes are derived from MESP1 positive precursors
[25], therefore it is reasonable to suggest that Mesp1Cre could delete
Hic2 in primitive erythrocyte precursors.
We next used in situ hybridisation to conﬁrm the change in ex-
pression of Hbb-bt seen on the microarray. Staining of wildtype embryos
revealed a low level of expression restricted to erythrocytes, which are
located largely within the heart tube (Fig. 2b, c). This result is con-
sistent with reports that primitive lineage erythrocytes express low le-
vels of deﬁnitive haemoglobins [16,17]. In the Mesp1Cre conditional
mutant we see strong upregulation of expression in erythrocytes
(Fig. 2d, e) conﬁrming the array results.
To quantify these changes we performed RT-qPCR on pools of
dissected hearts, using samples biologically independent from those
used for the microarray (Fig. 2f). Because the Mesp1Cre is a “Knock-In”
allele in which the CRE cassette replaces the Mesp1 coding sequence,
Cre positive embryos are heterozygous for Mesp1. To control for any
eﬀect ofMesp1 loss on the observed gene expression we compared three
genotypes: wildtype (Hic2FL/FL; Mesp1+/+), Cre only (Hic2+/+;
Mesp1Cre/+) and conditional Hic2 mutant (Mesp1Cre/+; Hic2FL/FL). In
wildtype embryos at E9.5, we observe strong expression of the em-
bryonic haemoglobins, Hbb-y and Hbb-bh1, at levels of one to 2.4 times
the level of GAPDH expression, with only weak expression of Hbb-bt
(0.12 of GAPDH; Fig. 2f). In contrast, in the wildtype at E13.5, Hbb-bt
expression has increased to 11.0 GAPDH, Hbb-y has increased to 11.9
GAPDH but Hbb-bh1 expression has dropped to 0.10 GAPDH. This result
indicates that primitive erythrocytes are still in circulation at this age
(deﬁnitive erythrocytes never express Hbb-y [17]) but that they have
undergone a maturational switch in gene expression from Hbb-bh1 to
Hbb-y [16]. The high expression of Hbb-bt at E13.5 indicates that de-
ﬁnitive-lineage erythrocytes are also in circulation at this age. Cre only
embryos exhibit a trend towards increased expression of embryonic
haemoglobins at both timepoints, although due to high variance be-
tween samples this is not signiﬁcant. The conditional Hic2mutant show
a signiﬁcant 5.6-fold increase in Hbb-bt expression at E9.5, from 0.12 to
0.67 GAPDH, conﬁrming the microarray result.
To separate out the relative eﬀects of Hic2 and Mesp1, which appear
to have opposing actions on erythrocyte gene expression, we calculated
the change in expression between genotypes diﬀering in only a single
variable (Fig. 2g). A comparison ofMesp1Cre/+ withMesp1Cre/+; Hic2FL/
FL shows us the relative contribution of Hic2 because both genotypes are
heterozygous for Mesp1 (Fig. 2g, grey bars). Similarly, a comparison of
Mesp1Cre/+ with wildtype (Hic2FL/FL) shows us the relative contribution
Fig. 2. HIC2 represses foetal haemoglobin expression in primitive erythrocytes.
a. X-gal staining of an E9.5 Hic2GT/+ embryo reveals strong reporter expression in the yolk sac (left) as well as in the heart tube (right).
b–e. In situ hybridisation to show expression of Hbb-bt at E9.5 in the wildtype (b,c) and mutant (d,e) embryo. Lower panels show an enlarged view of the boxed area above.
E = erythrocyte; HT = heart tube.
f–g. RT-qPCR analysis of gene expression in pooled heart samples. f and g show absolute expression (normalised to GAPDH) at E9.5 and E13.5 respectively while g shows the fold change
between the genotypes indicated at E9.5. P values indicate results of a one tailed t-test.
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of reducing Mesp1 to heterozygosity because both genotypes express
normal levels of Hic2 (Fig. 2g, blue bars). This analysis demonstrates a
signiﬁcant, but opposing action of Hic2 on the deﬁnitive Hbb-bt and the
embryonic Hbb-bh1 such that Hic2 acts to repress Hbb-bt while acti-
vating Hbb-bh1. Mesp1, in contrast, has no eﬀect on Hbb-bt but shows a
sub-threshold repression of Hbb-bh1, consistent with previous reports
demonstrating thatMesp1 acts to repress haematopoietic diﬀerentiation
in favour of cardiomyocyte diﬀerentiation in the mesoderm lineage
[26]. Therefore, these data suggest that Hic2 acts to promote embryonic
haemoglobin expression within MESP1+ primitive lineage ery-
throcytes while repressing deﬁnitive haemoglobin expression.
Nkx2.5Cre/+ targets deletion in the cardiomyocyte, vascular smooth
muscle and endothelial lineages [27,28]. Hic2FL/FL; Nkx2.5Cre/+ em-
bryos do not show embryonic lethality and have a mild phenotype [24],
and therefore we hypothesised that these embryos would not show
changes in haemoglobin expression. We performed an identical RT-
qPCR assay using Nkx2.5Cre in place of Mesp1Cre/+ (Fig. 2g). This
analysis demonstrated that loss of one copy of Nkx2.5 had no eﬀect on
haemoglobin expression, as expected (Fig. 2g, dark grey bars).
Nkx2.5Cre -mediated deletion of Hic2 had no eﬀect on expression of
Hbb-bt, consistent with the absence of Nkx2.5 in primitive-lineage yolk
sac precursors (Fig. 2g, orange bars). Surprisingly however, we ob-
served a signiﬁcant reduction in Hbb-bh1 expression in these embryos,
suggesting that Hic2 acts within NKX2.5+ precursors to promote em-
bryonic haemoglobin expression. This result is consistent with the ob-
servation that a population of NKX2.5+ haemogenic precursors exist in
the endocardium/endothelium of the outﬂow tract and atria at E9.5
[29,30]. Circulating NKX2.5-derived erythrocytes initially express Hbb-
bh1, but undergo maturational switching to express Hbb-bt in late ge-
station [29].
Thus our data are consistent with a role for Hic2 in maturational
haemoglobin switching within erythrocytes from two distinct embry-
ological sources. Hic2 promotes Hbb-bh1 expression in both lineages,
but represses Hbb-bt only in Mesp1-derived cells.
2.4. HIC2 regulates maturational isoform switching of cardiomyocytes
Creatine is an energy store used for fast production of ATP in highly
active tissues such as muscle and brain. Creatine kinase, which cata-
lyses the transfer of phosphate from creatine to ATP, exists as two
isoforms in the cytosol known as muscle (CKM) and brain (CKB), and
these form both homotypic and heterotypic dimers [19]. Expression is
regulated both spatially and over developmental time. CKB is expressed
in the early embryo in both brain and muscle; in brain it remains the
only isoform expressed but in heart and skeletal muscle, expression of
CKM is initiated in the foetus leading to expression ﬁrst of the CKM-CKB
heterodimer and later to expression of CKM alone [18].
Ckb was observed to be strongly expressed at both timepoints in our
microarray dataset (not shown), at a level of approximately 30× that
of Ckm in the wildtype embryo, consistent with its known embryonic
role in the heart. Ckm was found to be expressed at a low level at E9.5,
showing a signiﬁcant increase between E9.5 and E13.5. Ckm showed a
change of +6.78 in the Hic2 mutant at E9.5 (Fig. 1b, c).
We used both RT-qPCR and immunoﬂuorescence to verify these
changes. At E9.5, expression in the wildtype heart tube is negligible
(Fig. 3a, e). Strong mRNA and protein level expression is seen in the
conditional mutant at E9.5 (Fig. 3b, f), the latter localised to the heart
tube (Fig. 3b). At E13.5, strong CKM immunostaining is seen in the
ventricles and trabeculations of the wildtype heart (Fig. 3c), while RT-
qPCR assays indicate that mRNA expression increases 209-fold between
E9.5 and E13.5 (Fig. 3e). We again separated the eﬀect of Hic2 from
that ofMesp1 within the RT-qPCR data, demonstrating that Mesp1 has a
weak but signiﬁcant activator activity on Ckm expression (Fig. 3g; grey
bars), while Hic2 shows a strong repressor function, indicated by up-
regulation in the Hic2 conditional mutant relative to Mesp1Cre only
(Fig. 3g, blue bars). Analysis of Nkx2.5Cre mutants indicated that both
MESP1 and NKX2.5 mediated Hic2 deletion have a similar eﬀect
(Fig. 3g; blue and orange bars), consistent with the hypothesis that this
regulation occurs in cardiomyocytes derived from MESP1+, NKX2.5+
precursors.
Eukaryotic elongation factors such as Eef1α are a component of the
translational machinery. Eef1α exists as two isoforms, Eef1a1 and
Eef1a2. While Eef1a1 has a ubiquitous expression, Eef1a2 expression is
limited to brain, muscle and heart [31], a pattern strikingly similar to
that of creatine kinase Developmental isoform switching occurs such
that Eef1a1 is expressed in embryos while Eef1a2 is upregulated post-
nataly in speciﬁc tissues [31]. The array data suggests that Eef1a2 is
expressed precociously in the Hic2 mutant (Fig. 1c). We conﬁrmed by
RT-qPCR that Eef1a2 expression increases 10.4-fold between E9.5 and
E13.5 (Fig. 3e), and that there is a highly signiﬁcant expression increase
at E9.5 in both conditional Hic2 mutants (Fig. 3f, g). Hic2 also has an
antagonistic eﬀect to Mesp1 and Nkx2.5 on Eef1a2 expression, as for
Ckm (Fig. 3g).
Myoglobin (Mb) is closely related to haemoglobin but is expressed
in the sarcolemma of cardiomyocytes and skeletal muscle where it
transports oxygen to the mitochondria [32]. Only a single Mb gene
exists in mammals, but maturational isoform switching has been de-
monstrated between the two isoforms expressed in lamprey [33]. Mb
loss of function mice exhibit developmental delay and embryonic
lethality by E11.0 [5], a phenotype consistent with a functional re-
quirement in the foetus. Although we did not ﬁnd a signiﬁcant increase
in the E9.5 Hic2 mutant, our array data indicates a large 10-fold in-
crease in wildtypeMb expression between E9.5 and E13.5. We therefore
selected this gene for further analysis. In situ hybridisation data ob-
tained from the Eurexpress database indicates speciﬁc expression in the
mouse heart at E14.5 (Fig. 3d). We conﬁrmed by RT-qPCR that Mb
expression increases 46-fold between E9.5 and E13.5 (Fig. 3e). Con-
sistent with the array data, we did not see a change at E9.5 in the
conditional Hic2 knockout by RT-qPCR (Fig. 3f). However, this would
seem to be the result of the antagonistic eﬀect of Mesp1 because when
we separate the eﬀects of Hic2 and Mesp1 (as above) we observe a
signiﬁcant repressor function indicated by upregulation in the Hic2
conditional mutant relative to Mesp1Cre only (Fig. 3g, blue bars). De-
letion with Nkx2.5Cre has a similar eﬀect (Fig. 3g, orange bars), and our
data indicate that this transcription factor also has an activator eﬀect on
Mb expression (Fig. 3g,dark grey bars).
Thus, we have demonstrated that three developmentally-regulated
genes expressed in the foetal heart are repressed by Hic2 in the E9.5
embryo.
2.5. Hic2 regulates muscle-speciﬁc isoform expression in cardiomyocytes
Troponin is a component of the contractile machinery of striated
muscle that acts as a calcium-sensitive switch, serving to couple mo-
toneuron input to muscle contraction. Troponin is a complex of three
unrelated proteins: Troponin T (TNNT) binds to tropomyosin, which
regulates the interaction of myosin with actin, Troponin C (TNNC)
binds calcium ions while Troponin I (TNNI) is an inhibitory subunit.
Each exists in multiple isoforms which are regulated in a temporal and
spatial manner. Three isoforms of Troponin T exist, and in the adult,
these are expressed in non-overlapping domains in cardiac muscle
(TNNT2), slow skeletal muscle ﬁbres (TNNT1) and fast skeletal ﬁbres
(TNNT3) [9]. Expression of Tnnt2 in the mouse heart begins at E7.5, the
embryonic heart also transiently expresses Tnnt1 but never expresses
Tnnt3 [35]. Foetal skeletal muscle transiently expresses low levels of
Tnnt2 together with Tnnt1 and Tnnt3 [35].
Tnnt3 exhibits a 2.86-fold increase in the Hic2 Mesp1Cre conditional
mutant at E9.5 by microarray (Fig. 1b), but unlike Ckm, Eef1a2 and Mb,
its expression did not show an increase in the E13.5 wildtype (Fig. 1c);
in fact, the microarray data indicated a moderate decrease. Because
Tnnt3 is never normally expressed in the heart, we hypothesised that
Hic2 may function to regulate lineage-speciﬁc as well as maturational
I.M. Dykes et al. Journal of Molecular and Cellular Cardiology 114 (2018) 29–37
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Fig. 3. HIC2 represses foetal gene expression in cardiomyocytes.
a–c. CKM Immunostaining in the wildtype (a) and mutant (b) at E9.5, and in the wildtype at e13.5 (c). CKM expression is seen in the heart tube of the E9.5 Hic2 conditional mutant and in
the ventricles wall of the E13.5 wildtype heart.
d. In situ hybridisation to show Mb expression in the E14.5 heart (arrow; data obtained from Eurexpress [34]).
e–g. RT-qPCR analysis of gene expression in pooled heart samples. e and f show absolute expression (normalised to GAPDH) while g shows the fold change between the genotypes
indicated at E9.5. e illustrates the normal change in expression in wildtype embryos between E9.5 and E13.5 while f and g illustrate changes in mutant embryos at E9.5. P values indicate
results of a one tailed t-test.
Fig. 4. HIC2 represses cardiomyocyte expression of fast-twitch skeletal muscle troponins.
a, b. RT-qPCR analysis of gene expression in pooled heart samples. a shows absolute expression (normalised to GAPDH) while b shows the fold change between the genotypes indicated at
E13.5. p values indicate results of a one tailed t-test.
c–f. In situ hybridisation showing upregulation of skeletal muscle troponins in mutant hearts at E9.5 in the Mesp1cre conditional mutant. Arrows indicate tissue showing upregulated
expression. Expression of Tnnt3 is limited to the future atrium while Tnni2 is expressed throughout the heart tube.
g–h. Immunostaining to show upregulation of TNNT3 at E13.5. In wildtype embryos (Hic2FL/FL), TNNT3 expression (red) is seen in skeletal muscle (SM) but not in the heart. In the
Nkx2.5cre conditional mutant, TNNT3 expression is seen in both skeletal muscle and in the atria (A). We do not observe expression in the ventricle (V). DAPI counterstaining (blue)
indicates nuclei. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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isoform expression. RT-qPCR conﬁrmed the low expression level of
Tnnt3 in the wildtype heart at both E9.5 and E13.5, with no evidence
for a change in expression during this time (Fig. 4a, blue bars). RT-
qPCR further conﬁrmed the ectopic expression of Tnnt3 in the Hic2
Mesp1Cre conditional mutant, indicating a 3.6-fold expression increase
at E9.5 (Fig. 4a, yellow bars). Unlike developmentally regulated genes
such as Ckm, the eﬀect of Hic2 loss on Tnnt3 expression became more
pronounced with age, showing an 11.6-fold change at E13.5 (Fig. 4a,
yellow bars). In situ hybridisation conﬁrmed expression of Tnnt3 in the
heart tube of the Hic2 conditional mutant at E9.5 (Fig. 4c, d). Ectopic
expression appeared to be speciﬁc to the future atrium.
Troponin T genes are closely linked on the chromosome to Troponin
I genes in three Tnnt/Tnni pairs [10]. Three isoforms of Troponin I exist
and these are also expressed in cardiac, fast skeletal and slow skeletal
muscles. The fast skeletal Tnnt3 is linked to the fast skeletal Tnni2 on
chromosome 7 of the mouse (chromosome 10 in man) and there is
evidence that these two genes are co-regulated by a common regulatory
element [36,37]. RT-qPCR showed that Tnni2 is expressed at a level
over 50 times greater than Tnnt3 in the wildtype heart (Fig. 4a, blue
bars). Expression is signiﬁcantly increased in the Hic2 conditional
mutant only at E13.5, the change seen at E9.5 is not signiﬁcant by RT-
qPCR (Fig. 4a, yellow bars). This supports the hypothesis that dysre-
gulation of lineage-speciﬁc isoforms becomes more pronounced with
age.
We then asked whether isoforms associated with other muscle types
are also dysregulated in the Hic2 heart. We performed RT-qPCR assays
at E13.5 to maximise the chance of detecting an eﬀect and assayed the
expression of all three Troponin T and all three Troponin I genes. This
analysis indicated that the eﬀect of Hic2 loss is speciﬁc to the fast
skeletal muscle troponin isoforms: we did not detect an eﬀect on either
the slow skeletal isoforms or the cardiac isoforms (Fig. 4b, blue bars).
Mesp1 did not contribute to the regulation of these genes (Fig. 4b, grey
bars), although the data does demonstrate a requirement for Mesp1 for
expression of the cardiac isoform, Tnnt2 conﬁrming the known role of
this gene in promoting the cardiac fate [26].
NKX2.5 has previously been shown to regulate Tnnt3/Tnni2 ex-
pression [37] and therefore we asked whether HIC2 regulates Tnnt3/
Tnni2 expression within NKX2.5+ cardiomyocytes. Analysis of the
Nkx2.5Cre conditional mutant conﬁrmed the negative regulation of
Tnnt3 by NKX2.5 (Fig. 4b, dark grey bars), and also indicated NKX2.5
may positively regulate the slow skeletal troponin Tnnt1 (which is ex-
pressed in the early embryonic heart). Expression of both Tnnt3 and
Tnni2 are increased in the Hic2 Nkx2.5Cre conditional mutant (Fig. 4b,
orange bars), but the increase is weaker than that seen in the Mesp1CRE
mutant (Fig. 4b, compare blue and orange bars), perhaps indicating
that NKX2.5 and HIC2 are performing partially redundant functions at
this locus.
To gain a better understanding of the nature of this ectopic ex-
pression, we performed in situ hybridisation for Tnnt3 (Fig. 4c,d) and
Tnni2 (Fig. 4e,f) in the Hic2 Mesp1Cre conditional mutant at E9.5. This
analysis conﬁrmed upregulation of both genes in the mutant (arrows),
but indicated that while ectopic expression of Tnni2 is seen throughout
the heart tube, that of Tnnt3 is restricted to the atria. We then per-
formed immunostaining at E13.5 using an antibody against TNNT3
(Fig. 4g,h). A positive signal is seen to be restricted to skeletal muscle
ﬁbres in wildtype embryos (Fig. 4g), conﬁrming speciﬁcity of the an-
tibody. In the Hic2 Nkx2.5Cre conditional mutant we observe ectopic
TNNT3 expression, which is again restricted to the atria (Fig. 4h). These
data are consistent with previous reports of ectopic troponin expression
in other mutants showing ectopic expression of Tnnt3 in the Nkx2.5
hypomorph restricted to the atria [37], while Tnni2 can be ectopically
expressed in the ventricle (for example, in theMesp1Cre conditional Hira
mutant [36]).
3. Discussion
In this work, we have described a role for the transcription factor
HIC2 in regulating maturational isoform switching and muscle-speciﬁc
isoform expression within the cardiovascular and circulatory systems.
3.1. Developmental transitions in gene expression
There are two major physiological transitions during development
of the heart and circulation system, each of which is associated with
isoform transitions in cardiomyocytes and erythrocytes. The better
known is perhaps the major adjustment that occurs at birth, when re-
spiration begins and oxygen is delivered to the hypoxic foetus. This
results in a change in metabolism from the cytosol-based anaerobic
glycolysis of the foetus to the mitochondrial-based fatty acid metabo-
lism of the newborn [22]. This is accompanied by major changes in
expression of metabolic enzymes [22], as well as isoform switching
within both the cardiovascular and circulatory systems. One of the best
characterised switches is the transition in myosin heavy chain expres-
sion from Myh7 to Myh6 that takes place within the mouse heart [38].
There is also a switch in beta haemoglobin expression from foetal to
adult at this time in man (although not in mice) [4].
This switch is preceded by an earlier mid-gestation transition from
an embryonic to foetal gene expression. This is clearly seen in the
isoform switch from primitive to deﬁnitive (mouse)/foetal (man) hae-
moglobin expression, but is accompanied by other changes within
cardiomyocytes. Cardiomyocyte mitochondria undergo a structural al-
teration at this time, changing from a fragmented, round morphology at
E9.5 to an elongated, branching network at E13.5 [39]. Similarly, a
reorganisation of the contractile machinery occurs at this time, re-
sulting in generation of a mature striated cardiomyocyte morphology
[39].
Single cell transcriptomic proﬁling would seem to broadly support
this hypothesis, indicating the presence within cardiomyocytes of dis-
tinct transcriptional proﬁles at E9.5, E14.5 and P0 [40]. These authors
were able to identify a group of genes expressed in the early embryo
which are turned oﬀ by E14.5 and another set that showed the reverse
relationship [40], indicating that a transition occurs at about mid ge-
station.
3.2. A developmental clock regulates maturational isoform switching
Our data implicate HIC2 in the regulation of haemoglobin isoform
expression within yolk sac derived primitive lineage erythrocytes.
These cells are nucleated and remain in circulation for many days after
being produced, thus co-existing in the blood for a time with deﬁnitive
erythrocytes [16,17]. While deﬁnitive erythrocytes express only deﬁ-
nitive haemoglobins, primitive lineage erythrocytes express all hae-
moglobin isoforms and undergo a switch in expression whilst in cir-
culation [16,17,41]. We also provide evidence to suggest that HIC2
regulates haemoglobin expression in erythrocytes derived from
NKX2.5+ precursors, which are most likely derived from the en-
docardium. There is considerable evidence that switching of hae-
moglobin isoform expression occurs simultaneously within erythrocytes
derived from diﬀerent lineages and is therefore regulated by an in-
trinsic “developmental clock”. This concept was proposed following the
observation that cells maintained in culture [42] or transplanted into a
host animal [43] switch globin expression at a time determined by the
age of the donor tissue. A similar developmental clock has been pro-
posed to coordinate postnatal switching of troponin isoforms across the
cardiovascular system [44]. Our data suggests that a developmental
clock may coordinate changes in the circulatory system with changes in
the cardiovascular system. There are good reasons why changes in the
sarcomere apparatus should be coordinated with changes in metabolic
enzymes and in the oxygen delivery system. What signal HIC2 may be
responding to remains to be determined, but we speculate that this may
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be a response to hypoxia.
3.3. Myocyte speciﬁc gene expression
Cardiac and skeletal muscles share a common contractile ability and
utilise a set of homologous sarcomeric proteins to do this. However,
cardiomyocytes are derived from lateral plate mesoderm while most
skeletal myocytes are derived from the paraxial mesoderm (although
facial muscle shares a common embryonic origin to cardiomyocytes, the
cardiopharyngeal ﬁeld [45,46]). Thus, these cell types are analogous
structures that have converged upon a common function. Although
each troponin isoform is restricted to a speciﬁc muscle type in the adult,
developing muscles sometimes co-express two or more isoforms [35]. It
would therefore appear that a mechanism exists to suppress expression
of alternative isoforms as muscles mature and that this may be dis-
rupted in the absence of HIC2, leading to ectopic expression of the fast
skeletal TNNT3 isoform.
There are parallels in this with a similar phenomenon observed
during diﬀerentiation of sensory neurons. These cells are derived from
two distinct embryological lineages (neural crest and neurogenic pla-
code) but converge on a common gene expression programme. This
process appears to be orchestrated by two key transcription factors,
BRN3A (POU4F1) and ISL-1. Interestingly, one function of these tran-
scription factors is to repress expression of non-sensory neuron genes,
for example BRN3A represses genes normally expressed by cardio-
myocytes (including Nkx2.5) [47] while ISL-1 does the same for genes
associated with spinal motoneurons [48]. Mouse mutants exhibit acti-
vation of an ectopic programme of gene expression associated with
these cell types [47–49], despite the distinct embryonic lineages from
which these cell types arise.
3.4. Maturational and muscle-speciﬁc isoform regulation are linked
Single cell sequencing of Nkx2.5+/− cardiomyocytes at E14.5 has
shown that these cells express higher levels of Myh7 than wildtype cells
[40], indicative of a delay in maturational isoform switching. The same
cells also show reduced expression of Ckm and Eef1a2 [40], devel-
opmentally-regulated genes that we found to be increased in the E9.5
Hic2 heart. This is consistent with our results (Fig. 3g) and suggests that
NKX2.5 may act later in development than HIC2 to promote rather than
repress foetal gene expression. Ectopic expression of the fast skeletal
troponins Tnnt3 and Tnni2 is seen in the Nkx2.5 hypomorph mutant
[37], and this is supported by our results showing increased expression
in the Nkx2.5CRE. Therefore, HIC2 and NKX2.5 appear to regulate a
common set of downstream genes in both maturational and muscle-
speciﬁc isoform switching. It is noteworthy that both Hic2 and Nkx2.5
exhibit a haploinsuﬃcient cardiac phenotype in mice [24] [50]. An-
other transcription factor, PROX1, has been shown to repress Tnnt3/
Tnni2 expression both in cardiomyocytes and in slow-twitch skeletal
muscle [51]. While HIC2 is not expressed in skeletal muscle [24], a
close homologue, HIC1, is expressed here [52] and we speculate that
HIC1 may regulate lineage-speciﬁc isoform expression in skeletal
muscle.
3.5. Mechanisms of isoform-speciﬁc expression
The Brg1/Brm-associated-factor (BAF) chromatin remodelling
complex has been shown to play a critical role in regulating myosin
heavy chain isoform switching. The BAF complex recruits histone
deacetylase to the Myh6 locus to repress expression, while activating
Myh7 through recruitment of poly (ADP ribose) polymerase (PARP) to a
locus control region located between these two adjacent genes on the
chromosome [38]. Isoform switching of haemoglobin expression also
involves a locus control region, which interacts with individual globin
promoters by chromatin looping [53]. A similar mechanism may op-
erate in Tnnt3/Tnni2 regulation. NKX2.5 occupies a site within the Lsp1
gene, which is located between the paired Tnnt3 and Tnni2 genes, and is
not expressed in cardiomyocytes [37]. This site is also bound by the
histone modiﬁer HIRA [36], and the Hira mouse mutant, in common
with those of the histone deacetylases Hdac1 and Hdac2 [54], exhibits
ectopic expression of Tnnt3/Tnni2. Thus, a model is emerging in which
histone modiﬁcations and chromatin remodelling at an organiser region
regulates transcription of isoforms located in cis on the chromosome.
We hypothesise that the function of transcription factors such as
NKX2.5 and HIC2 may be to integrate developmental signals by re-
cruiting these modiﬁers to such regulatory loci. HIC2 consists of an
array of DNA-binding zinc ﬁngers at the C-terminus linked to an N-
terminal BTB/POZ domain [23], which mediates transcriptional re-
pression and acts as a protein-protein interaction domain. Little func-
tional data exists for HIC2, but its homologue HIC1 has been shown to
interact with chromatin remodelling complexes such as the NuRD
(nucleosome remodelling and histone deacetylase) [55] and SWI/SNF
ATP-dependent [56] chromatin remodelling complexes.
4. Glossary
A atrium
BPM beats per minute
BTB/POZ a protein domain named after proteins in which it is found
(Bric-a-brac, Tramtrack, Broad-Complex/Poxviruses and Zinc
ﬁngers)
Ckb creatine kinase, brain
Ckm creatine kinase, muscle
CRE CRE recombinase (causes REcombination), a recombinase
enzyme derived from the P1 bacteriophage which recognises
the LoxP site
E erythrocyte
E9.5 Embryonic day 9.5. By convention, day E0.5 is midday on the
day following conception.
Eef1a eukaryotic elongation factor 1a
FL ﬂoxed allele, in which LoxP sites ﬂank one or more exons.
GT genetrap allele, in which a cassette consisting of a splice
acceptor site, a LacZ coding sequence and a polyadenylation
signal are randomly inserted into the genome. If inserted into
a coding sequence may cause a loss of function mutation.
Hbb-bh haemoglobin Z, beta-like embryonic chain
Hbb-bs haemoglobin, beta adult s chain
Hbb-bt haemoglobin, beta adult t chain
Hbb-y haemoglobin Y, beta-like embryonic chain
Hic2 hypermethylated in Cancer 2
HT heart tube
KO knockout, or loss-of-function allele
LOXP short DNA sequence recognised by the CRE enzyme
Mb myoglobin
Mesp1 mesoderm posterior 1
NuRD nucleosome remodelling and histone deacetylase complex
P0 postnatal day 0, or the day of birth
SM skeletal muscle
SWI/SNF SWItch/Sucrose Non-Fermentable, a chromatin remodelling
complex
TNNC troponin C, calcium
TNNI troponin I, inhibitory
TNNT troponin T, tropomyosin
V ventricle
WT wildtype allele
X-GAL X-galactosidase staining, indicates expression of LacZ.
5. Methods
5.1. Mouse genetics and breeding
Mouse lines used in this study have been previously described [24].
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Hic2GT:Hic2Gt(RRN127)Byg; MGI:4329590
Hic2FL:Hic2Gt(E225A08)Wrst; MGI:3919233
Nkx2.5CRE:Nkx2–5tm1(cre)Rjs; MGI:2654594
Mesp1CRE:Mesp1tm2(cre)Ysa; MGI:2176467
Throughout the paper, mice carrying the Hic2FL allele in the ab-
sence of a Cre allele are considered wildtype. All mouse procedures
were carried out in accordance with UK Home Oﬃce regulations.
Timed matings were performed and pregnant dams harvested by
cervical dislocation.
5.2. RNA extraction from heart
Whole heart containing circulating erythrocytes was dissected from
embryos lacking a phenotype at both E9.5 and E13.5 and stored in
RNA-Later (Ambion). RNA was prepared using the RNA mini kit
(Qiagen). Three genotypes were analysed for each conditional mutant:
CKO (Cre/+; Hic2FL/FL), CRE (Cre/+; Hic2+/+) and WT
(+/+;Hic2FL/FLor +/+;Hic2FL/+). Two knock-in CRE lines were used
in this study: Mesp1Cre and Nkx2.5Cre. 4–6 hearts were pooled per
sample and six independent biological replicates (each itself a pooled
sample) were performed for each genotype group, three were used for
microarray analysis and an independent three pools used for sub-
sequent qPCR analysis.
5.3. Microarray analysis
Single stranded cDNA was prepared using the Ambion WT
Expression kit (Ambion) and this was hydrolysed and labelled using the
Aﬀymetrix genechip terminal labelling and hydrolyzing kit (Aﬀymetrix,
Santa Clara, USA). Probes were hybridised to the Mouse Exon 1.0 ST
whole transcript array genechip (Aﬀymetrix) at UCL Genomics.
Data were analysed using the core gene predictions of the
Aﬀymetrix Gene Expression Console and normalised using the RMA
algorithm. Data were pre-ﬁltered to select for those genes showing an
expression value> 100 in the upregulated condition and to remove
probes for which no annotation exists. We then performed a two tailed
t-test to test the null hypothesis of no diﬀerence between the wildtype
and knockout conditions. This gave 174 upregulated and 457 down-
regulated genes. Applying an arbitrary threshold of mean fold
change> 1.5 across 3 replicates reduced this number to give a ﬁnal list
of 34/29 upregulated/downregulated changed genes.
CEL and CHP ﬁles of these microarray data have been submitted to
the Gene Expression Omnibus, accession numbers: E13.5 data
GSE56430 and E9.5 data GSE100125.
5.4. qRT-PCR
RNA was reverse transcribed using the Quantitect Reverse
Transcription kit (Qiagen). qPCR was performed using SYBR Green
technology on a Step One machine (Applied Biosystems). Expression
was measured relative to that of GAPDH and signiﬁcance assessed by
performing a one or two tailed t-test on the Ct values. Graphs show
mean ± standard deviation.
5.5. In situ hybridisation
In situ hybridisation was performed on cryosections with DIG la-
belled probes using standard techniques. Brieﬂy, tissue was permeabi-
lised with a 10 minute digestion in 10 μg/ml proteinase K, hybridised at
55 °C with 1 ng/ml DIG-RNA probe and probe detected with a sec-
ondary alkaline phosphatase sheep anti DIG polycolonal antibody
(Roche). Matched control and mutant sections were collected and
processed on the same slide to ensure that hybridisation and colour
development conditions were equal.
5.6. Immunoﬂuorescence
Commercial goat anti CKM (Santa Cruz 15,164) and rabbit anti
TNNT3 (Sigma HPA 037810) polyclonal antibodies were used. A citrate
antigen retrieval step was used for the TNNT3 antibody. Alexa-con-
jugated secondary antibodies were used (Life Technologies, Carlsbad
USA). Sections were mounted in Vectashield medium containing DAPI
(Vector laboratories).
5.7. X-gal staining
β-Galactosidase staining was performed using standard methods.
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